AR-Targeting Drugs (Defactinib, Cilengitide, Dasatinib, Celecoxib)

Beyond V-ATPase inhibitors, several other drug classes are being explored to re-sensitize cancer cells to anoikis by reversing anoikis resistance (AR): defactinib (a FAK inhibitor), cilengitide (an αv integrin inhibitor), dasatinib (a SRC inhibitor), and celecoxib (which targets p130Cas signaling).

Not all translate clinically — cilengitide showed a strong preclinical mechanism but failed to improve overall survival in Phase III glioblastoma trials, a cited cautionary tale for anoikis-resistance-targeted therapy.